OPRD1 rs569356 polymorphism has an effect on plasma norbuprenorphine levels and dose/kg-normalized norbuprenorphine values in individuals with opioid use disorder
 
Yazarlar (6)
Prof. Dr. Dilek Akyüzlü Ankara Üniversitesi, Türkiye
Doç. Dr. Selin ÖZKAN KOTİLOĞLU Kırşehir Ahi Evran Üniversitesi, Türkiye
Mustafa Danışman Ankara Training & Res Hosp AMATEM Clin
Prof. Dr. Ceylan Bal Ankara Yıldırım Beyazıt Üniversitesi, Türkiye
Begüm Oğur Ankara Training & Res Hosp AMATEM Clin
Gamze Zengin İspir Ankara Training & Res Hosp AMATEM Clin
Makale Türü Özgün Makale (SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale)
Dergi Adı ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY (Q1)
Dergi ISSN 1382-6689 Wos Dergi Scopus Dergi
Dergi Tarandığı Indeksler SCI-Expanded
Makale Dili Türkçe Basım Tarihi 06-2023
Cilt / Sayı / Sayfa 100 / 0 / 104143–0 DOI 10.1016/j.etap.2023.104143
Makale Linki http://dx.doi.org/10.1016/j.etap.2023.104143
Özet
This study aimed to determine the effects of nine OPRM1, OPRD1 and OPRK1 polymorphisms on plasma BUP and norbuprenorphine (norBUP) concentrations and various treatment responses in a sample of 122 patients receiving BUP/naloxone. Plasma concentrations of BUP and norBUP were detected by LC–MS/MS. PCR-RFLP method was used to genotype polymorphisms. OPRD1 rs569356 GG had significantly lower plasma norBUP concentration (p = 0.018), dose- (p = 0.049) and dose/kg-normalized norBUP values (p = 0.036) compared with AA. Craving and withdrawal symptoms were significantly higher in OPRD1 rs569356 AG+GG relative to AA. There was a statistically significant difference between the OPRD1 rs678849 genotypes in the intensity of anxiety (13.5 for CT+TT and 7.5 for TT). OPRM1 rs648893 TT (18.8 ± 10.8) was significantly different to CC+CT (14.82 ± 11.3; p = 0.049) in view of the …
Anahtar Kelimeler
Opioid use disorder | Norbuprenorphine | Opioid receptors | Pharmacodynamics | Craving | Withdrawal